Abstract 2208P
Background
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of non-small cell lung cancer which is frequently associated with EBV infection and displays high levels of immune cell infiltration. Immunotherapy, thus, is an attractive therapeutic strategy for the disease but the treatment response has been inconsistent, indicating a gap in our understanding of the tumor microenvironment (TME) of PLELC.
Methods
Imaging mass cytometry was used in this study to map the different cellular components and interactions in 33 PLELCs at different stages (19 early-stage, 6 medium-stage, and 8 advanced-stage).
Results
Component analysis showed differential B and Treg cell composition in the TME as cancer progresses. In spatial analyses, we discovered a convergent melting trend of immune cell distribution across different stages in the tumor and non-tumor regions (p<0.05). We also identified anti-tumor immunity markers assigned to specific cellular interactions (p<0.01). In the neighborhood analysis, we found that myeloid cells near the tumor may attenuate the ability of antigenic immune responses. Furthermore, we identified two spatial structures within the TME that could impact the infiltration of immune cells and the relapse of patients, and disease relapse in patients is associated with the level of immune cells inside the tumor region (p<0.01) and fibroblasts surrounding the tumor.
Conclusions
Our findings indicate that TME is heterogeneous and dynamic along the disease progression of PLELC such that cellular components, spatial interactions, and immune cell infiltration may play a significant role in disease recurrence. Moreover, profiling the TME may be helpful for understanding and selecting different immune treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2140P - Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO & EORTC OligoCare cohort
Presenter: Daniela Greto
Session: Poster session 07
2141P - Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): A systematic literature review (SLR)
Presenter: Nikhila Indukuri
Session: Poster session 07
2142P - Criteria for the choice of therapeutic ceiling in the hospitalized oncology patient: Healthcare impact of the multidisciplinary committee with the Intensive Care Unit (ICU)
Presenter: María Esperanza Guirao García
Session: Poster session 07
2143P - Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis
Presenter: Osman Sutcuoglu
Session: Poster session 07
2144P - The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
Presenter: Oriol Mirallas
Session: Poster session 07
2145P - Thromboembolic disease associated with cyclin-dependent kinase inhibitors in patients with breast cancer
Presenter: Javier López Robles
Session: Poster session 07
2146P - Cancer-associated thrombosis clinic: Experience of the Medical Oncology Department of a hospital in Spain
Presenter: Laura Ortega Morán
Session: Poster session 07
2147P - Thrombotic recurrence and bleeding complications in non-small cell lung carcinoma (NSCLC) patients with venous thromboembolism (VTE)
Presenter: Irene Gonzalez Caraballo
Session: Poster session 07
2148P - Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
Presenter: Lorenzo Gervaso
Session: Poster session 07
2149P - Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Presenter: Francisco Pelegrín Mateo
Session: Poster session 07